Davita Inc Stock Price, News & Analysis

DaVita Inc. (NYSE: DVA) announced that its CFO, Joel Ackerman, will participate in a fireside chat with investors at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 11 a.m. EDT. Stakeholders can access the live webcast by registering on the Bank of America Securities page.

DaVita is a leading kidney care provider, serving 203,000 patients across 2,815 U.S. outpatient dialysis centers and 339 centers globally.

DaVita reported Q1 2022 financial results, highlighting a net income of $162 million, down from $237 million year-over-year. Diluted EPS was $1.61, a 10.1% decrease from the previous quarter, influenced by COVID-19 impacts and wage increases. Consolidated revenues reached $2.818 billion. Operating income fell to $338 million with a 12.0% margin. There was a decline in U.S. dialysis treatments by 2.2% from Q4 2021. DaVita continues to provide care to over 241,800 patients across 3,155 centers globally, despite opening nine new centers in Q1. The company also repurchased 2.1 million shares during this period.

DaVita Inc. (NYSE: DVA) will hold its quarterly conference call on May 5, 2022, at 5 p.m. EDT to discuss first quarter results. Results will be released after market close that same day. The call will be accessible via webcast on the DaVita Investor Relations webpage. DaVita is a leading kidney care provider, serving 203,000 patients at 2,815 outpatient dialysis centers in the U.S. and 339 centers across ten other countries. The company aims to enhance care quality globally.

Rockwell Medical (RMTI) announced a significant partnership expansion with DaVita (DVA), featuring a $7.5 million initial equity investment and an amended supply agreement. This collaboration aims to stabilize Rockwell's concentrates business, enabling profitable operation while ensuring reliable supply for dialysis treatment. The agreement includes a potential additional $7.5 million investment, contingent on meeting certain conditions. Rockwell Medical emphasizes its vital role in the dialysis sector, with ambitions to broaden its business through ongoing discussions with other key customers.

DaVita Inc announced the appointment of Jason M. Hollar as an independent director effective May 6, 2022. Hollar brings over 25 years of financial experience, currently serving as CFO of Cardinal Health, with a revenue of over $160 billion in 2021. His previous roles include CFO positions at Tenneco and Sears Holdings. CEO Javier Rodriguez expressed confidence in Hollar's ability to enhance DaVita's strategy for kidney care transformation. With Hollar's addition, DaVita's board consists of 10 directors with diverse backgrounds.

DaVita and partners successfully increased COVID-19 vaccine access for end-stage kidney disease (ESKD) patients, reducing racial disparities. A study published in JAMA Internal Medicine shows that vaccination coverage rose significantly among Hispanic, Black, and Asian patients at dialysis centers. Results highlighted that by June 2021, vaccination rates for Hispanic and Asian patients exceeded those of white patients. Overall, 50.7% of vaccinated patients received their shots in a dialysis clinic. Researchers advocate for prioritizing dialysis centers for future vaccine allocations.

Pathalys Pharma, a late-stage biopharmaceutical company, has been established with seed financing from DaVita Venture Group and Catalys Pacific. The company focuses on chronic kidney disease (CKD) treatments, starting with the investigational drug upacicalcet, which has demonstrated efficacy in Japan. Pathalys plans to conduct two phase 3 clinical trials in the U.S. for upacicalcet to treat secondary hyperparathyroidism in hemodialysis patients. Neal Fowler, a former CEO at Liquidia, has been appointed as CEO, enhancing the leadership team's industry experience.